Ketamine Tablets vs Nasal Spray (Spravato)

Ketamine tablets and esketamine nasal spray (brand name Spravato) are both ketamine-based treatments for depression, but they differ in almost every practical dimension: regulatory status, formulation, setting, cost structure, and access. Understanding these differences is important because the choice between them often depends more on insurance coverage and logistics than on pharmacological superiority.

The Formulations

Ketamine tablets: Racemic ketamine hydrochloride (containing equal parts of the S- and R-enantiomers) in oral tablet form. Compounded by pharmacies. Used off-label for depression and pain.

Spravato: Esketamine hydrochloride (the S-enantiomer only) in a nasal spray device. Manufactured by Janssen Pharmaceuticals. FDA-approved specifically for treatment-resistant depression (2019) and major depressive disorder with suicidal ideation (2020).

The chemical difference matters: esketamine is roughly 3-4 times more potent at the NMDA receptor than the R-enantiomer, but racemic ketamine delivers both enantiomers, which may have complementary therapeutic effects. Whether one formulation is clinically superior to the other remains debated.

Key Differences

Regulatory Status

Tablets: Off-label use. Legal and common in medicine, but the FDA has not specifically approved oral ketamine for any psychiatric indication.

Spravato: FDA-approved for TRD and MDD with suicidal ideation. Approved under a Risk Evaluation and Mitigation Strategy (REMS) program that mandates in-clinic administration and monitoring.

Administration Setting

Tablets: Can be taken at home with a treatment monitor. No clinical infrastructure required beyond a prescriber and pharmacy.

Spravato: Must be administered in a certified healthcare facility. The patient self-administers the nasal spray under observation, then must be monitored for at least 2 hours before being cleared to leave. The REMS program prohibits take-home use.

Cost and Insurance

Tablets: $8-$30 per dose out of pocket. Not typically covered by insurance. Monthly total of $200-$600 including clinical oversight.

Spravato: List price of approximately $590-$885 per session (depending on dose). Often covered by insurance due to FDA approval, with copays varying widely ($0-$300 per session depending on plan). Without insurance, the cost is substantially higher than tablets.

The insurance dynamic is the critical financial differentiator. For patients with good insurance coverage, Spravato may be less expensive out of pocket. For patients paying cash, tablets are dramatically cheaper.

Bioavailability

Tablets: 10-25% (oral, with full first-pass metabolism)

Spravato: 25-50% (intranasal, partial first-pass bypass through nasal mucosal absorption)

Dosing

Tablets: Flexible dosing adjusted by the prescriber. Weight-based or fixed-dose protocols. Frequency determined clinically.

Spravato: Fixed doses of 56 mg or 84 mg per session. FDA-approved schedule is twice weekly for weeks 1-4, then weekly for weeks 5-8, then weekly or biweekly thereafter.

Efficacy

Spravato: Phase 3 RCTs demonstrated statistically significant improvement vs. placebo in TRD. The evidence base is large and regulatory-grade. However, effect sizes have been described as moderate, and some trials failed to meet their primary endpoint.

Tablets: Smaller evidence base, but consistently positive. Direct head-to-head trials between Spravato and racemic oral ketamine are limited. Some clinicians and researchers believe racemic ketamine (both enantiomers) may offer advantages over esketamine alone, but this has not been proven in rigorous comparative trials.

When Tablets Are the Better Choice

• Paying out of pocket (substantially lower cost)
• Need for home-based treatment
• Preference for dosing flexibility
• Geographic distance from a Spravato-certified clinic
• Pain indications (Spravato is not approved for pain)
• Preference for racemic ketamine

When Spravato Is the Better Choice

• Good insurance coverage that reduces out-of-pocket cost
• Preference for an FDA-approved product
• Clinical situations where supervised administration is preferred
• Patients who value the regulatory validation of FDA approval
• Access to a certified Spravato center

Practical Considerations

The in-clinic requirement for Spravato is a significant practical burden for many patients. Each session requires travel to a certified facility, 2+ hours of monitoring, and a driver home. For patients who receive treatment twice weekly during induction, this means 4+ clinic visits in the first two weeks — a substantial time commitment.

Ketamine tablets, by contrast, allow dosing at home on the patient's schedule. For patients with work obligations, childcare responsibilities, or transportation challenges, this flexibility is often the deciding factor.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• Mayo Clinic: Treatment-Resistant Depression — Mayo Clinic resource on treatment-resistant depression diagnosis, management, and emerging therapies